• Bertram, L, Tanzi RE. 2008. Thirty years of Alzheimer's disease genetics: the implications of systemic meta analysis. Nature Rev Neurosci 9:768778.
  • Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. 2007. Forecasting the global burden of Alzheimer's disease. Alzheimer Dementia 3:186191.
  • Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, on behalf of the dimebon investigators. 2008. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207215.
  • Glabe CC. 2005. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38:167177.
  • Hardy J. 2006. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9:151153.
  • Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353356.
  • Li H-G, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. 2007. Amyloid-β in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 321:823829.
  • Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379397.
  • Williams M. 2009. Progress in Alzheimer's disease drug discovery: an update. Curr Opin Invest Drugs 10:2334.
  • Yankner BA. 1996. New clues to Alzheimer's disease: unraveling the roles of amyloid and tau. Nat Med 2:850852.